Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention

Publisher： Bentham Science Publishers

E-ISSN： 1875-5992|13|7|971-978

ISSN： 1871-5206

Source： Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol.13, Iss.7, 2013-09, pp. : 971-978

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 10, 2013-12 ,pp. : 1552-1564

Bentham Science Publishers

Access to resources Recommend Favorite

Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 7, 2013-09 ,pp. : 1048-1056

Bentham Science Publishers

Access to resources Recommend Favorite

Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway

By      

Oncology Reports, Vol. 33, Iss. 6, 2015-01 ,pp. : 3085-3092

Spandidos Publications

Access to resources Recommend Favorite

βhydroxyisovalerylshikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling

By            

Oncology Letters, Vol. 10, Iss. 6, 2015-01 ,pp. : 3434-3442

Spandidos Publications

Access to resources Recommend Favorite

Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 5, Iss. 1, 2010-01 ,pp. : 29-57

Bentham Science Publishers

Access to resources Recommend Favorite